Published in Invest New Drugs on June 06, 2012
Targeting sonic hedgehog-associated medulloblastoma through inhibition of Aurora and Polo-like kinases. Cancer Res (2013) 0.92
Dual Aurora A and JAK2 kinase blockade effectively suppresses malignant transformation. Oncotarget (2014) 0.88
Targeting Aurora kinase-A downregulates cell proliferation and angiogenesis in neuroblastoma. J Pediatr Surg (2013) 0.87
Molecular profiling of childhood cancer: Biomarkers and novel therapies. BBA Clin (2014) 0.86
Aurora kinases as targets in drug-resistant neuroblastoma cells. PLoS One (2014) 0.84
Scientific Rationale Supporting the Clinical Development Strategy for the Investigational Aurora A Kinase Inhibitor Alisertib in Cancer. Front Oncol (2015) 0.81
Issues in interpreting the in vivo activity of Aurora-A. Expert Opin Ther Targets (2014) 0.80
Dasatinib suppression of medulloblastoma survival and migration is markedly enhanced by combining treatment with the aurora kinase inhibitor AT9283. Cancer Lett (2014) 0.77
The Aurora kinase inhibitors in cancer research and therapy. J Cancer Res Clin Oncol (2016) 0.76
ABCG2 impairs the activity of the aurora kinase inhibitor tozasertib but not of alisertib. BMC Res Notes (2015) 0.75
Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods (1983) 114.35
Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat Rev Drug Discov (2002) 6.97
Mutations in aurora prevent centrosome separation leading to the formation of monopolar spindles. Cell (1995) 5.56
Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc Natl Acad Sci U S A (2000) 5.53
Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol (2005) 4.99
Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors. J Biol Chem (2005) 4.62
Histone deacetylase inhibitors in cancer therapy. J Clin Oncol (2009) 4.58
Aurora-A - a guardian of poles. Nat Rev Cancer (2005) 4.11
A study of some variables in a tetrazolium dye (MTT) based assay for cell growth and chemosensitivity. Br J Cancer (1987) 3.62
Application of a new approach for the quantitation of drug synergism to the combination of cis-diamminedichloroplatinum and 1-beta-D-arabinofuranosylcytosine. Cancer Res (1990) 3.24
Aurora-kinase inhibitors as anticancer agents. Nat Rev Cancer (2004) 3.19
Inhibition of aurora B kinase blocks chromosome segregation, overrides the spindle checkpoint, and perturbs microtubule dynamics in mitosis. Curr Biol (2002) 3.17
Initial testing of the aurora kinase A inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP). Pediatr Blood Cancer (2010) 2.99
Aurora kinases as anticancer drug targets. Clin Cancer Res (2008) 2.92
Aurora-A kinase maintains the fidelity of early and late mitotic events in HeLa cells. J Biol Chem (2003) 2.89
The Aurora kinases: role in cell transformation and tumorigenesis. Cancer Metastasis Rev (2003) 2.64
HDAC inhibitors: clinical update and mechanism-based potential. Biochem Pharmacol (2007) 2.16
MLN8054, a small-molecule inhibitor of Aurora A, causes spindle pole and chromosome congression defects leading to aneuploidy. Mol Cell Biol (2007) 1.79
A novel histone deacetylase pathway regulates mitosis by modulating Aurora B kinase activity. Genes Dev (2006) 1.70
Interaction and feedback regulation between STK15/BTAK/Aurora-A kinase and protein phosphatase 1 through mitotic cell division cycle. J Biol Chem (2001) 1.68
Histone deacetylase inhibitors: a new class of potential therapeutic agents for cancer treatment. Clin Cancer Res (2002) 1.50
Pediatric phase I trial and pharmacokinetic study of vorinostat: a Children's Oncology Group phase I consortium report. J Clin Oncol (2010) 1.42
Histone deacetylase 3 localizes to the mitotic spindle and is required for kinetochore-microtubule attachment. Proc Natl Acad Sci U S A (2008) 1.30
Targeted disruption of Aurora A causes abnormal mitotic spindle assembly, chromosome misalignment and embryonic lethality. Oncogene (2008) 1.21
Pediatric phase I trial and pharmacokinetic study of MLN8237, an investigational oral selective small-molecule inhibitor of Aurora kinase A: a Children's Oncology Group Phase I Consortium study. Clin Cancer Res (2012) 1.13
Bortezomib interactions with chemotherapy agents in acute leukemia in vitro. Cancer Chemother Pharmacol (2005) 1.10
Initial testing (stage 1) of vorinostat (SAHA) by the pediatric preclinical testing program. Pediatr Blood Cancer (2009) 1.08
Histone deacetylase inhibitors induce premature sister chromatid separation and override the mitotic spindle assembly checkpoint. Cancer Res (2007) 1.04
Aurora A, Aurora B and survivin are novel targets of transcriptional regulation by histone deacetylase inhibitors in non-small cell lung cancer. Cancer Biol Ther (2008) 1.03
Inhibitors of histone deacetylases induce tumor-selective cytotoxicity through modulating Aurora-A kinase. J Mol Med (Berl) (2007) 1.01
Antitumor activity of MLN8054, an orally active small-molecule inhibitor of Aurora A kinase. Proc Natl Acad Sci U S A (2007) 3.27
Characterization of Alisertib (MLN8237), an investigational small-molecule inhibitor of aurora A kinase using novel in vivo pharmacodynamic assays. Clin Cancer Res (2011) 2.35
MLN8054, a small-molecule inhibitor of Aurora A, causes spindle pole and chromosome congression defects leading to aneuploidy. Mol Cell Biol (2007) 1.79
The investigational Aurora kinase A inhibitor MLN8237 induces defects in cell viability and cell-cycle progression in malignant bladder cancer cells in vitro and in vivo. Clin Cancer Res (2013) 1.62
Localization of human TACC3 to mitotic spindles is mediated by phosphorylation on Ser558 by Aurora A: a novel pharmacodynamic method for measuring Aurora A activity. Cancer Res (2007) 1.62
MDM2 inhibition sensitizes neuroblastoma to chemotherapy-induced apoptotic cell death. Mol Cancer Ther (2006) 1.34
Folate pathway genetic polymorphisms are related to attention disorders in childhood leukemia survivors. J Pediatr (2007) 1.29
Phase I study of the proteasome inhibitor bortezomib in pediatric patients with refractory solid tumors: a Children's Oncology Group study (ADVL0015). J Clin Oncol (2004) 1.29
The inhibition of Aurora A abrogates the mitotic delay induced by microtubule perturbing agents. Cell Cycle (2009) 1.20
Nanoshell-mediated photothermal therapy improves survival in a murine glioma model. J Neurooncol (2010) 1.13
Plasma and cerebrospinal fluid pharmacokinetics of imatinib after administration to nonhuman primates. Clin Cancer Res (2004) 1.13
Poly(ADP-ribose) polymerase inhibitor ABT-888 potentiates the cytotoxic activity of temozolomide in leukemia cells: influence of mismatch repair status and O6-methylguanine-DNA methyltransferase activity. Mol Cancer Ther (2009) 1.11
Bortezomib interactions with chemotherapy agents in acute leukemia in vitro. Cancer Chemother Pharmacol (2005) 1.10
Characteristics and outcome of pediatric patients enrolled in phase I oncology trials. Oncologist (2008) 1.09
Phase I study of MLN8237--investigational Aurora A kinase inhibitor--in relapsed/refractory multiple myeloma, non-Hodgkin lymphoma and chronic lymphocytic leukemia. Invest New Drugs (2013) 1.09
Impact of body composition on pharmacokinetics of doxorubicin in children: a Glaser Pediatric Research Network study. Cancer Chemother Pharmacol (2008) 0.99
Ras-driven transcriptome analysis identifies aurora kinase A as a potential malignant peripheral nerve sheath tumor therapeutic target. Clin Cancer Res (2012) 0.98
A phase II study of O6-benzylguanine and temozolomide in pediatric patients with recurrent or progressive high-grade gliomas and brainstem gliomas: a Pediatric Brain Tumor Consortium study. J Neurooncol (2011) 0.96
Aurora A is differentially expressed in gliomas, is associated with patient survival in glioblastoma and is a potential chemotherapeutic target in gliomas. Cell Cycle (2012) 0.94
Vascular-targeted photothermal therapy of an orthotopic murine glioma model. Nanomedicine (Lond) (2012) 0.93
Amblyopia treatment outcomes. J AAPOS (2005) 0.92
Phase I assessment of new mechanism-based pharmacodynamic biomarkers for MLN8054, a small-molecule inhibitor of Aurora A kinase. Cancer Res (2010) 0.92
Phase 1 trial of O6-benzylguanine and BCNU in children with CNS tumors: a Children's Oncology Group study. Pediatr Blood Cancer (2008) 0.91
Response to MLN8237 in pancreatic cancer is not dependent on RalA phosphorylation. Mol Cancer Ther (2013) 0.91
The selective Aurora-A kinase inhibitor MLN8237 (alisertib) potently inhibits proliferation of glioblastoma neurosphere tumor stem-like cells and potentiates the effects of temozolomide and ionizing radiation. Cancer Chemother Pharmacol (2014) 0.89
Phase I pharmacokinetic and pharmacodynamic study of temozolomide in pediatric patients with refractory or recurrent leukemia: a Children's Oncology Group Study. J Clin Oncol (2007) 0.89
The minimum occlusion trial for the treatment of amblyopia. Ophthalmology (2002) 0.86
Educational paper. The development of new therapies for pediatric oncology. Eur J Pediatr (2010) 0.86
Plasma and cerebrospinal fluid pharmacokinetics of thalidomide and lenalidomide in nonhuman primates. Cancer Chemother Pharmacol (2011) 0.84
Preclinical pharmacokinetic/pharmacodynamic/efficacy relationships for alisertib, an investigational small-molecule inhibitor of Aurora A kinase. Cancer Chemother Pharmacol (2013) 0.84
The novel kinase inhibitor EMD1214063 is effective against neuroblastoma. Invest New Drugs (2014) 0.84
Methotrexate pharmacokinetics in infants with acute lymphoblastic leukemia. Cancer Chemother Pharmacol (2006) 0.83
Phase I clinical trial of intrathecal gemcitabine in patients with neoplastic meningitis. Cancer Chemother Pharmacol (2007) 0.82
Phase I trial and pharmacokinetic study of raltitrexed in children with recurrent or refractory leukemia: a pediatric oncology group study. Clin Cancer Res (2005) 0.81
Plasma and cerebrospinal fluid pharmacokinetic study of BNP1350 in nonhuman primates. Cancer Chemother Pharmacol (2004) 0.80
Oxymatrine protects against myocardial injury via inhibition of JAK2/STAT3 signaling in rat septic shock. Mol Med Rep (2013) 0.79
Synergy of karenitecin and mafosfamide in pediatric leukemia, medulloblastoma, and neuroblastoma cell lines. Pediatr Blood Cancer (2008) 0.79
Plasma and cerebrospinal fluid pharmacokinetics of valproic acid after oral administration in non-human primates. Cancer Chemother Pharmacol (2007) 0.79
Pharmacokinetics of doxorubicin in pregnant women. Cancer Chemother Pharmacol (2014) 0.78
A high-throughput liposome substrate assay with automated lipid extraction process for PI 3-kinase. J Biomol Screen (2008) 0.78
Phase I and pharmacokinetic study of thalidomide with carboplatin in children with cancer. J Clin Oncol (2004) 0.77
Pharmacokinetics of intrathecal gemcitabine in nonhuman primates. Clin Cancer Res (2002) 0.77
Preparation and characterization of thermosensitive PNIPAA-coated iron oxide nanoparticles. Nanotechnology (2008) 0.77
A phase-1 pharmacokinetic optimal dosing study of intraventricular topotecan for children with neoplastic meningitis: a Pediatric Brain Tumor Consortium study. Pediatr Blood Cancer (2012) 0.76
Combined Anti-PLGF and Anti-Endostatin Treatments Inhibit Ocular Hemangiomas. Cell Physiol Biochem (2015) 0.76
Pharmacokinetics and pharmacogenomics of daunorubicin in children: a report from the Children's Oncology Group. Cancer Chemother Pharmacol (2014) 0.76
A Polymorphism in the FGFR4 Gene Is Associated With Risk of Neuroblastoma and Altered Receptor Degradation. J Pediatr Hematol Oncol (2016) 0.75
Increased expression of CCN2 in the red flashing light-induced myopia in guinea pigs. Biomed Res Int (2013) 0.75
A rabbit model of spontaneous thrombosis induced by lipopolysaccharide. J Atheroscler Thromb (2014) 0.75
Nitrogen-containing polyhydroxylated aromatics as HIV-1 integrase inhibitors: synthesis, structure-activity relationship analysis, and biological activity. J Enzyme Inhib Med Chem (2012) 0.75
Plasma and cerebrospinal fluid pharmacokinetics of tasidotin (ILX-651) and its metabolites in non-human primates. Cancer Chemother Pharmacol (2008) 0.75
Diplopia in a patient with Hashimoto's thyroiditis: A case report and literature review. Medicine (Baltimore) (2017) 0.75
Supervised Deep Feature Embedding With Handcrafted Feature. IEEE Trans Image Process (2019) 0.75
Please don't call my mom: pediatric consent and confidentiality. Clin Pediatr (Phila) (2008) 0.75